Lantheus Holdings Inc (LNTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com11-07

Consolidated Net Revenue: $378.7 million, an increase of 18.4% year over year. Radiopharmaceutical Oncology Sales: $259.8 million, up 20.6%, driven by PYLARIFY. Precision Diagnostics Revenue: $103.7 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481788942?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Q59oOwnOem3YZ0TWz_W3Fw--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/3dbb701955bdde94a2c5491fb2b34065","is_english":true,"pubTime":"2024-11-07 15:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481788942","market":"us","top_or_hot":-1,"title":"Lantheus Holdings Inc (LNTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Consolidated Net Revenue: $378.7 million, an increase of 18.4% year over year.\nRadiopharmaceutical Oncology Sales: $259.8 million, up 20.6%, driven by PYLARIFY.\nPrecision Diagnostics Revenue: $103.7 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lantheus-holdings-inc-lnth-q3-070804277.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lantheus Holdings Inc (LNTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLantheus Holdings Inc (LNTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 15:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/lantheus-holdings-inc-lnth-q3-070804277.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Consolidated Net Revenue: $378.7 million, an increase of 18.4% year over year.\nRadiopharmaceutical Oncology Sales: $259.8 million, up 20.6%, driven by PYLARIFY.\nPrecision Diagnostics Revenue: $103.7 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lantheus-holdings-inc-lnth-q3-070804277.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LNTH","symbol_name":"Lantheus Holdings, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/lantheus-holdings-inc-lnth-q3-070804277.html","article_id":"2481788942","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Q59oOwnOem3YZ0TWz_W3Fw--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/3dbb701955bdde94a2c5491fb2b34065"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481788942","pubTimestamp":1730963284,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Consolidated Net Revenue: $378.7 million, an increase of 18.4% year over year.Precision Diagnostics Revenue: $103.7 million, an increase of 7.7%.DEFINITY Sales: $77 million, up 14.3% year over year.TechneLite Revenue: $20.5 million, down 12% due to prior year opportunistic sales.Strategic Partnerships and Other Revenue: $15.3 million, up 108.3%.Gross Profit Margin: 68.2%, an increase of 109 basis points.Operating Expenses: 24.6% of net revenue, 111 basis points higher year over year.Operating Profit: $165.1 million, an increase of 18.3%.Adjusted Net Income: $124.1 million, an increase of 20.4%.Operating Cash Flow: $175.1 million, $58.3 million over prior year.Free Cash Flow: $159.3 million, an increase of $57.1 million over the prior year.GuruFocus has detected 4 Warning Sign with LNTH.PYLARIFY, Lantheus Holdings Inc 's PSMA PET imaging agent, is on track to reach blockbuster status with over $1 billion in sales in 2024.Lantheus Holdings Inc  has a strong pipeline with promising late-s","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LNTH":"Lantheus Holdings, Inc."},"translate_title":"Lantheus Holdings Inc(LNTH)2024年第三季度收益看涨期权亮点：强劲的收入增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":1},"content_text":"Consolidated Net Revenue: $378.7 million, an increase of 18.4% year over year.\nRadiopharmaceutical Oncology Sales: $259.8 million, up 20.6%, driven by PYLARIFY.\nPrecision Diagnostics Revenue: $103.7 million, an increase of 7.7%.\nDEFINITY Sales: $77 million, up 14.3% year over year.\nTechneLite Revenue: $20.5 million, down 12% due to prior year opportunistic sales.\nStrategic Partnerships and Other Revenue: $15.3 million, up 108.3%.\nGross Profit Margin: 68.2%, an increase of 109 basis points.\nOperating Expenses: 24.6% of net revenue, 111 basis points higher year over year.\nOperating Profit: $165.1 million, an increase of 18.3%.\nNet Income (GAAP): $131 million.\nAdjusted Net Income: $124.1 million, an increase of 20.4%.\nAdjusted EPS: $1.70, an increase of 15.6%.\nOperating Cash Flow: $175.1 million, $58.3 million over prior year.\nFree Cash Flow: $159.3 million, an increase of $57.1 million over the prior year.\nCash and Cash Equivalents: $866.4 million.\nFull Year Revenue Guidance: Narrowed to $1.51 billion to $1.52 billion.\nFull Year Adjusted EPS Guidance: Narrowed to $6.65 to $6.70.\n\n\nWarning! GuruFocus has detected 4 Warning Sign with LNTH.\n\nRelease Date: November 06, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nPYLARIFY, Lantheus Holdings Inc (NASDAQ:LNTH)'s PSMA PET imaging agent, is on track to reach blockbuster status with over $1 billion in sales in 2024.\nDEFINITY, the company's ultrasound-enhancing agent, saw a 14% year-over-year increase in sales, driven by market share gains and high market growth.\nThe CMS decision to pay separately for specialized diagnostic radiopharmaceuticals starting January 1, 2025, is expected to enhance patient access and support innovation.\nLantheus Holdings Inc (NASDAQ:LNTH) has a strong pipeline with promising late-stage diagnostic product candidates for Alzheimer's disease, MK-6240 and NAV-4694.\nThe company reported a significant increase in free cash flow, reaching $159.3 million, up $57.1 million from the previous year.\n\n Negative Points \n\nPYLARIFY experienced a sequential revenue decline due to traditional third-quarter seasonality and net price impacts from strategic partnerships.\nThe company's TechneLite revenue decreased by 12% due to opportunistic sales in the prior year not repeated in this year's third quarter.\nOperating expenses increased by 111 basis points, driven by higher R&D investments and sales and marketing efforts.\nThe implied fourth-quarter guidance appears light, with expectations of increased R&D expenses impacting earnings.\nThe reclassification of the company's 2027 convertible debt to a current liability may distort working capital statistics.\n\n Q & A Highlights \nQ: Could you talk about the factors behind PYLARIFY's 3Q revenues and how this should flow into the rest of the year? A: Paul Blanchfield, President, explained that PYLARIFY grew 20% year over year in Q3 and is on track to grow mid-20% in 2024, reaching blockbuster status. The sequential decline was due to traditional third-quarter seasonality, net price impact from strategic partnerships, and intentional tradeoffs due to product availability. They expect to remain the PSMA PET imaging agent of choice and grow revenue sequentially in Q4.\nQ: Can you clarify the CMS reimbursement rates for 2025 and the implied Q4 guidance? A: Paul Blanchfield confirmed that CMS will pay separately for radiopharmaceutical diagnostics above a $630-day arithmetic mean cost, with PYLARIFY's 2025 payment rate matching its current rate. Robert Marshall, CFO, noted that Q4 revenue is expected to be higher than Q3, with PYLARIFY on track for mid-20% growth for the year. The step-down in EPS from Q3 to Q4 is due to increased R&D expenses.\nQ: Why use the term \"sustain\" instead of \"grow\" for PYLARIFY's $1 billion franchise in 2025? A: Brian Markison, CEO, clarified that they anticipate volume growth for PYLARIFY next year. Paul Blanchfield added that strategic partnerships have caused net price compression, but they expect the market to grow with increasing incidence, prevalence, and adoption of PSMA PET imaging.\nQ: Can you provide more details on the Alzheimer's diagnostic pipeline and its differentiation from current options? A: Jeff Humphrey, Chief Medical Officer, highlighted that their Alzheimer's diagnostics, MK-6240 and NAV-4694, have high sensitivity and low off-target binding, offering anatomical imaging that correlates with symptom severity. Paul Blanchfield added that the market potential is significant, with PET imaging complementing serological tests and leveraging existing infrastructure.\nQ: How should we think about the royalties from PYLCLARI and the potential growth of FLYCARDO? A: Paul Blanchfield noted that PYLCLARI's financial impact is minimal in the near term as it ramps up in Europe. For FLYCARDO, GE Healthcare holds commercialization rights, and Lantheus will receive milestones and royalties. The cardiac imaging market is sizable, and they are optimistic about its growth.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481788942"}